Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

20. April 2021 06:34 ET | Quelle: Genmab A/S

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2021

Company Announcement Net sales of DARZALEX® in the first quarter of 2021 totaled USD 1,365 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. Copenhagen, Denmark;...
19. April 2021 03:51 ET | Quelle: Genmab A/S

Transactions in connection with share buy-back program

Company Announcement COPENHAGEN, Denmark; April 19, 2021 – Genmab A/S (Nasdaq: GMAB). On February 23, 2021 Genmab announced the initiation of a share buy-back program to mitigate dilution from...
13. April 2021 16:44 ET | Quelle: Genmab A/S

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; April 13, 2021 – Genmab A/S (Nasdaq: GMAB) In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,...
13. April 2021 16:39 ET | Quelle: Genmab A/S

Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees and a New Member of Management in Genmab

Company Announcement COPENHAGEN, Denmark; April 13, 2021 – Genmab A/S (Nasdaq: GMAB) Following Genmab A/S’ Annual General Meeting held on April 13, 2021, the Company’s Board of Directors met to...
13. April 2021 09:26 ET | Quelle: Genmab A/S

Passing of Genmab A/S’ Annual General Meeting

Company Announcement At Genmab A/S’ Annual General Meeting held today April 13, 2021, the Annual Report for 2020 was approvedDischarge was given to the Board of Directors and the Executive Management...
12. April 2021 03:55 ET | Quelle: Genmab A/S

Transactions in connection with share buy-back program

Company Announcement COPENHAGEN, Denmark; April 12, 2021 – Genmab A/S (Nasdaq: GMAB). On February 23, 2021 Genmab announced the initiation of a share buy-back program to mitigate dilution from...
09. April 2021 16:00 ET | Quelle: Genmab A/S

Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer

Company Announcement FDA action date is Oct 10, 2021BLA submission supported by positive pivotal innovaTV 204 trial results presented at the European Society of Medical Oncology Virtual Congress...
06. April 2021 03:21 ET | Quelle: Genmab A/S

Transactions in connection with share buy-back program

Company Announcement COPENHAGEN, Denmark; April 6, 2021 – Genmab A/S (Nasdaq: GMAB). On February 23, 2021 Genmab announced the initiation of a share buy-back program to mitigate dilution from warrant...
30. März 2021 01:21 ET | Quelle: Genmab A/S

Genmab Announces European Marketing Authorization for Kesimpta® (ofatumumab) in Relapsing Multiple Sclerosis

Company Announcement Novartis receives European approval for Kesimpta® (ofatumumab) for the treatment of relapsing forms of multiple sclerosis in adults Approval follows positive opinion by European...
29. März 2021 11:19 ET | Quelle: Genmab A/S

Genmab Files Annual Report with the U.S. Securities and Exchange Commission

Media Release Copenhagen, Denmark, March 29, 2021 Genmab filed Form 20-F for the financial year 2020 with the U.S. SEC Genmab A/S (Nasdaq: GMAB) announced today that it has filed its Annual Report...

Vorherige Seite

Nächste Seite